Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jsat.2020.108221 http://scihub22266oqcxt.onion/10.1016/j.jsat.2020.108221 33303254!7711199!33303254     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Subst+Abuse+Treat 2021 ; 124 (ä): 108221 Nephropedia Template TP {{tp|p=33303254|t=2021. Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges |pdf=|usr=}}{{33303254}} gab.com Text Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges JO: J Subst Abuse Treat http://www.kidney.de/pget.php?&tw=1&pmid=33303254 #FOAvip The COVID-19 pandemic has presented challenges for traditional models of opioid use disorder treatment worldwide. Depot buprenorphine became available in Australia shortly before the height of the COVID-19 pandemic. This timing provided us an opportunity to examine the utilization and uptake of depot buprenorphine, and to understand the particular benefits and implementation challenges associated with this new formulation of opioid agonist treatment. Twit Text FOAVip Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges ????J Subst Abuse Treat http://www.kidney.de/pget.php?&tw=1&pmid=33303254 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33303254 #FOAvip English Wikipedia <ref>{{Cite pmid|33303254}}</ref> Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges #MMPMID33303254 Arunogiri S; Lintzeris N J Subst Abuse Treat 2021[May]; 124 (ä): 108221 PMID33303254show ga The COVID-19 pandemic has presented challenges for traditional models of opioid use disorder treatment worldwide. Depot buprenorphine became available in Australia shortly before the height of the COVID-19 pandemic. This timing provided us an opportunity to examine the utilization and uptake of depot buprenorphine, and to understand the particular benefits and implementation challenges associated with this new formulation of opioid agonist treatment. |Australia[MESH] |Buprenorphine/supply & distribution/*therapeutic use[MESH] |COVID-19/*prevention & control[MESH] |Delayed-Action Preparations/*therapeutic use[MESH] |Humans[MESH] |Injections, Subcutaneous[MESH] |Narcotic Antagonists/*therapeutic use[MESH] |Opiate Substitution Treatment[MESH] |Opioid-Related Disorders/*drug therapy/rehabilitation[MESH]Depot buprenorphine during COVID-19 in Australia: Opportunities and ch(epmc).pdf DeepDyve Pubget Overpricing